tbuckley/cabot-search huggingface dataset:
1‐desamino‐8‐arginine‐vasopressin corrects the hemostatic defects in type 2B von Willebrand's disease
Authors: L.P. McKeown, G. Connaghan, O. Wilson, K. Hansmann, P. Merryman, H.R. Gralnick
Journal: American Journal of Hematology (1996)

DDAVP is effective treatment in most types of von Willebrand's disease; however, in type 2B von Willebrand's disease the use of DDAVP has been contraindicated due to DDAVP-induced thrombocytopenia. Several reports have confirmed the thrombocytopenic effects of DDAVP and the presence of circulating platelet aggregates in type 2B von Willebrand's disease. We have infused three type 2B patients with DDAVP. The three patients had different mutations of their vWf. All three patients had a missense mutation which resulted in a single amino acid substitution in the disulfide loop of the A1 domain. Administration of 20 μg of DDAVP resulted in significant elevations of factor VIII, vWf antigen, and ristocetin cofactor levels. In contrast to other studies, DDAVP did not induce or enhance thrombocytopenia in these three patients. When blood was obtained by fingerstick and diluted into sodium oxalate (Unopette®) or EDTA (Microvette®), the platelet counts did not change over 4 hr. In contrast, blood collected directly into evacuated tubes containing sodium citrate, lithium heparin, or EDTA consistently demonstrated varying degrees of thrombocytopenia and platelet clumping. We also observed a shortening of the preinfusion bleeding time over the 4 hr period. All three patients have been studied twice and each has shown consistent results. DDAVP appears to be a useful form of treatment in type 2B vWd. (This article is a US Government work and, as such, is in the public domain in the United States of America.) © 1996 Wiley-Liss, Inc.
Phase II study of oral ENMD-2076 administered to patients (pts) with advanced soft tissue sarcoma (STS).
Authors: Herbert H. F. Loong, Martin E. Blackstein, Abha A. Gupta, David Hogg, Lindsay Culala, Kjirsten Nyquist-Schultz, Stephanie Baker, Lisa Wang, Albiruni R. A. Razak
Journal: Journal of Clinical Oncology (2014)

10528 Background: The use of angiogenic and Aurora kinase inhibitors has been shown to abrogate tumor growth in STS. ENMD-2076 is an oral Aurora A and angiogenic kinase inhibitor that has demonstrated single-agent activity in STS cell lines and inhibition of sarcoma growth for a patient in a phase 1 clinical trial setting. Methods: This is a single-center, open-labeled phase II study of ENMD-2076 in advanced STS pts treated with ≤1 line of prior therapy in the advanced/metastatic setting. Pts were commenced on 275mg daily dose (on a 28-day cycle. Treatment-emergent adverse events were assessed by CTCAE (4.0). Radiographic or clinical tumor measurements occurred every 2 cycles (RECIST 1.1). Results: 10 pts were enrolled from 2/2013 – 11/2013 and evaluable for efficacy. Median age is 58 yrs (41 – 72). Male: Female 1:9. Histology: Leiomyosarcoma / pleomorphic sarcoma / angiosarcoma: 7/2/1. Pts received the following prior systemic therapies: doxorubicin/gemcitabine/others: 2/3/5. At time of abstract submission, median follow-up is at 7 months (2-12). 3 pts continue on study. Median number of cycles administered per pt = 2 (1-8). 2 pts had confirmed partial response (PR) and 1 pt with confirmed stable disease (SD) of > 6 months. Clinical benefit rate (PR+SD >6 months) was 30%. Median OS has not been reached. Median PFS at 1.8 months (95% CI: 1.2 – not reached). ENMD-2076 has generally been well tolerated with primarily grade 1 and 2 adverse events (AEs). Specifically, drug-induced hypertension occurred in 6 pts (grade 1-2: 4 pts, grade 3: 2 pts). Proteinuria, all grade 1-2, occurred in 6 pts. Other drug related grade 3 or 4 AEs include (pts): elevated transaminases (1), leukopenia (1), and diarrhea (1). 1 pt developed Posterior Reversible Encephalopathy Syndrome (PRES) presenting as grade 4 loss of consciousness at Cycle 1 Day 15 required ICU admission. Full neurological recovery was attained after cessation of treatment. Conclusions: ENMD-2076 has shown activity in patients with advanced STS, with meaningful clinical benefits and a side effects profile typical of this class of agent. PRES is a rare but fully reversible side effect of ENMD-2076. Clinical trial information: NCT01719744.
"One-Hand" Double-Loop Method of Tying Knots
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Protecting Building Environments From Airborne Chemical, Biologic, or Radiologic Attacks
Journal: JAMA (2002)

In November 2001, following the discovery that letters containing Bacillus anthracis had been mailed to targeted locations in the United States, the Secretary of the U.S. Department of Health and Human Services requested site assessments of an array of public- and private-sector buildings by a team of engineers and scientists from CDC's National Institute for Occupational Safety and Health (NIOSH). In November 2001, this team assessed six buildings, including a large hospital and medical research facility, a museum, a transportation building, two large office buildings, and an office/laboratory building. In January 2002, additional building assessments were conducted at CDC campuses in Atlanta and, in April 2002, at a large, urban transportation facility. A total of 59 buildings were evaluated during this 5-month period.
Reviews elsewhere
Authors: Michael Kew
Journal: Hepatology (1991)

of benign hepatic diseases characterized by parenchymal inflammation, including acute hepatitis, CAH, cirrhosis and PBC.For example, Huang and Liaw found raised TBG levels in 80% of patients with CAH and 71% of those with posthepatitic cirrhosis.The high serum levels of the binding protein in these conditions parallel those of the aminotransferases, implying that TBG leaks into the circulation from damaged hepatocytes.Because cirrhosis is one of the more important disorders to be differentiated from HCC, the specificity of TBG as a marker of this tumor might also be questioned.As reported by Huang and Liaw and ourselves (a), cirrhotic patients with inactive cirrhosis (i.e., with normal serum aminotransferase levels) are known to have normal serum TBG levels.Because HCC usually coexists with inactive rather than active cirrhosis, Huang and Liaw propose that a raised serum TBG value in a patient with a normal ALT level may be a useful marker of HCC.Another possible role for TBG in the diagnosis of HCC arises from the observations of Alexopoulos et al. (3).In long-term monitoring of cirrhotic patients they observed that for those patients in whom HCC developed, the serum TBG concentration rose, whereas for those patients in whom HCC did not develop, the level remained the same or even decreased.The raised TBG values preceded the clinical recognition of the tumor and in some cases even an increase in the serum a-fetoprotein level.They have therefore suggested that serum TBG may be of value in the early recognition of HCC arising in a cirrhotic liver.
Is risankizumab better than secukinumab in the treatment of plaque psoriasis?
Journal: British Journal of Dermatology (2021)

Plaque psoriasis is a common inflammatory disease that causes raised, flaky plaques or patches on the skin. An abnormal immune system can be an important cause of psoriasis. Risankizumab and secukinumab are biologic drugs that are injected under a patient’s skin to treat different parts of the immune system. Both drugs are approved in the U. S. and E. U. to treat moderate‐to‐severe plaque psoriasis.
Boxing injuries
Authors: J P Payne
Journal: BMJ (1993)

<h3>Background</h3> Intimate partner violence (IPV) against women and child maltreatment (CM) are major public health problems and human rights issues and may have shared causes. However, their overlap is understudied. We investigated the prevalence of IPV and CM, their co-occurrence in households and possible shared risk factors, in the general population of a Brazilian urban setting. <h3>Methods</h3> Prospective population-based birth cohort, including over 3500 mother–child dyads with maternal reports on both IPV and CM when children were 4 years old. Eleven neighbourhood, family and parental risk factors were measured between birth and age 4 years. Bivariate and multivariate Poisson regression models with robust variance were used to test which potential risk factors were associated with IPV, CM and their co-occurrence. <h3>Results</h3> The prevalence of any IPV and CM were 22.8% and 10.9%, respectively; the co-occurrence of both types of violence was 5%. Multivariate analyses showed that the overlap of IPV and CM was strongly associated with neighbourhood violence, absence of the child’s biological father, paternal antisocial behaviour in general and a mother–partner relationship characterised by high levels of criticism, maternal depression and younger maternal age. A concentration of many risk factors among 10% of the population was associated with a sixfold increase in risk for overlapping IPV and CM compared with households with no risk factors. <h3>Conclusion</h3> IPV and CM share important risk factors in the family and neighbourhood environments and are particularly common in households with multiple social disadvantages and family difficulties. Integrated preventive interventions are needed.
Reply to Per-Uno Malmström and Bruce J. Trock's Letter to the Editor re: Richard J. Sylvester, Willem Oosterlinck, Sten Holmang, et al. Systematic Review and Individual Patient Data Meta-analysis of Randomized Trials Comparing a Single Immediate Instillation of Chemotherapy After Transurethral Resection with Transurethral Resection Alone in Patients with Stage pTa–pT1 Urothelial Carcinoma of the Bladder: Which Patients Benefit from the Instillation? Eur Urol. In press. http://dx.doi.org/10.1016…
Authors: Richard Sylvester
Journal: European Urology (2015)
<i>Erratum:</i> Vol. 69, No. 46
Authors: Corinne Thompson, Jennifer Baumgartner, Carolina Pichardo, Brian Toro, Lan Li, Robert Arciuolo, ; Pui, Ying Chan, Judy Chen, Gretchen Culp, Alexander Davidson, Katelynn Devinney, Alan Dorsinville, Michele English, Ana Fireteanu, Laura Graf, Anita Geevarughese, Sharon Greene, Kevin Guerra, Mary Huynh, Christina Hwang, Maryam Iqbal, Jillian Jessup, Jillian Knorr, Ramona Lall, Julia Latash, Ellen Lee, Kristen Lee, Wenhui Li, Robert Mathes, Emily Mcgibbon, Natasha Mcintosh, Matthew Montesano, Miranda Moore, Kenya Murray, Stephanie Ngai, Marc Paladini, Rachel Paneth-Pollak, Hilary Parton, Eric Peterson, Renee Pouchet, Jyotsna Ramachandran, Kathleen Reilly, Jennifer Sanderson Slutsker, Gretchen Van Wye, Amanda Wahnich, Ann Winters, Marcelle Layton, Lucretia Jones, Vasudha Reddy, Anne Fine, Lall Is The
Journal: MMWR Morbidity and Mortality Weekly Report (2020)
Adoption of Hospital Policies for Prevention of Perinatal Group B Streptococcal Disease—United States, 1997
Journal: JAMA (1998)

Group B streptococcal (GBS) infections are the leading bacterial cause of disease and deaths among newborns in the United States. In 1993, the annual cost of caring for newborns with sepsis caused by group B Streptococcus was an estimated $294 million. A survey of hospital GBS disease prevention practices in 1994 indicated that those hospitals with a prenatal screening policy had fewer neonatal GBS disease cases. In 1996, to promote a coordinated approach to prevention, CDC issued consensus guidelines about GBS disease prevention that were endorsed by the American College of Obstetricians and Gynecologists and the American Academy of Pediatrics. These consensus guidelines recommend using either a screening-based strategy or a risk-based strategy for identifying women who should receive intrapartum antimicrobial prophylaxis. To evaluate adoption of the consensus guidelines, in 1997, hospitals in eight surveillance areas were surveyed, and the results were compared with findings of a similar survey conducted in 1994. The proportion of hospitals with prevention policies in each site was compared with the site's rate of early-onset disease to assess the impact of the prevention policies. This report presents the survey findings, which indicate that more hospitals have adopted GBS disease prevention policies since issuance of the consensus guidelines.
American Public Health Association, Twelfth Annual Meeting.
Journal: JAMA (1884)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Cardiovascular Hemodynamics
Authors: Sheldon H. Steiner
Journal: JAMA (1968)

<h3>To the Editor:—</h3> The problem that Dr. Ream presents has not been solved to everyone's satisfaction at the present time. There are certainly profound anatomical changes in the lung bases in mitral stenosis, but the mechanisms by which these anatomic changes occur are not readily defined. If the response of the pulmonary bed is differentially under active vascular control, this cannot be readily demonstrated. It is likely that these changes take considerable time to evolve and that venous pressure reasonably plays a role in the development of these anatomical changes. Certainly, in a normal lung, there is absent apical perfusion in the seated or erect position but this does not result in profound anatomic changes in the basal portions of the lung. The distribution of pulmonary blood flow is gravity dependent, and this can be demonstrated readily by the observations of pulmonary blood flow distribution during acceleration in which the
Trials of Colony Stimulating Factors Grow, So Do Applications, Side Effects
Journal: JAMA (1988)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Approval of a New Rapid Test for HIV Antibody
Journal: JAMA (2002)

On November 7, 2002, the Food and Drug Administration announced approval of the OraQuick Rapid HIV-1 Antibody Test (OraSure Technologies, Inc., Bethlehem, Pennsylvania) for use by trained personnel as a point-of-care test to aid in the diagnosis of infection with human immunodeficiency virus type 1 (HIV-1). OraQuick is a simple, rapid test that can detect antibodies to HIV in fingerstick whole blood specimens and provide results in as little as 20 minutes [corrected]. The test has been categorized as moderate complexity under the Clinical Laboratory Improvement Amendments of 1988 (CLIA). A second FDA-approved moderate-complexity rapid HIV test, Single Use Diagnostic System for HIV-1 (Abbott-Murex Inc., Norcross, Georgia), remains available in the United States for use with serum or plasma specimens.
International Meeting on Hormonal Therapy of Prostatic Diseases: Basic and Clinical Aspects
Journal: JNCI Journal of the National Cancer Institute (1986)

International Meeting on Hormonal Therapy of Prostatic Diseases: Basic and Clinical Aspects Get access JNCI: Journal of the National Cancer Institute, Volume 77, Issue 5, November 1986, Pages 1173–1174, https://doi.org/10.1093/jnci/77.5.1173-f Published: 01 November 1986
Syphilis
Authors: Robert F. Tilley
Journal: New England Journal of Medicine (1955)

FIVE years have elapsed since the last progress report on syphilis appeared in this journal. During this period the value of penicillin has been established not only in early infectious syphilis but also in late symptomatic syphilis. The worth of the broad-spectrum antibiotics has been demonstrated. The treponema-immobilization test shows great promise in eliminating false-positive reactions from true or syphilitic reactors. Seldom has a single serologic procedure been accepted so enthusiastically. Long-term observations have delineated the course of both treated and untreated patients. The World Health Organization has undertaken the conduct of mass campaigns against venereal and nonvenereal treponemal diseases. . . .
Subject index11July, pp. 1-226; August, pp. 227-466; September, part 1, pp. 467-640; part 2, pp. S1-S40; October, part 1, pp. 641-816; part 2, pp. S41-S100; November, part 1, pp. 917-1018; part 2, pp. S101-S116; December, part 1, pp. 1019-304; part 2, pp. S117-S150.
Journal: Journal of Allergy and Clinical Immunology (2003)
The Diary
Authors: John W. Burnside
Journal: JAMA (1987)

Ask ten doctors about their reaction to patients who come to the office with a diary of their medical problems and eleven will groan. It takes a fair amount of body focus to make someone want to record it on paper. For some, I guess, it fills empty hours. Maybe it's a way of fighting against other signals that suggest he or she is unimportant. If it's on paper it must be true and it must be significant. Rarely is a diary an aid to bad memory. If anything, folks who record symptoms have extraordinary memories. The importance of the information is inversely proportional to the length of the diary. Harold Yocum kept the most extensive diary of any patient I have ever seen. Harold was a dapper little guy, standing perhaps five feet four. A local retail clerk, he was always impeccably dressed: sharp creases on his suit trousers
Single-dose treatment of gonorrhoea.
Journal: BMJ (1973)

pulmonale.A further group of scores includes appetite, weight loss, exercise tolerance, and attitude to the disease.Hepatic fibrosis or portal hypertension were not included in the scoring system, perhaps because of their relative rarity, though severe hepatic disease undoubtedly influences the outlook in some cases.It is not clear whether this system has advantages over previous ones, particularly since it relies heavily on pulmonary function tests, which are not easy to perform accurately in young children.Moreover, some criteria such as changes in chest radiographs and physical examination of the chest are difficult to standardize, while a certain diagnosis of cor pulmonale in its early stages is difficult to make in cystic fibrosis.'1 12There is not yet, nor is there likely to be, a com- pletely satisfactory prognostic scoring system for cystic fibrosis, particularly since the disease is peculiarly subject to unexpected fluctuations in its course.Consequently, though a physician will be helped by his own attempts to evaluate his cases in a standardized manner, he cannot usually give a precise prognosis in terms of months or years.Patient and parents are unlikely to be helped by being offered a numerical score instead of hope."3
Recertification 1977
Authors: ROBERT G. PETERSDORF
Journal: Annals of Internal Medicine (1977)

Editorial Notes1 May 1977Recertification 1977ROBERT G. PETERSDORF, M.D., M.A.C.P.ROBERT G. PETERSDORF, M.D., M.A.C.P.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-86-5-651 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptDuring this year the American College of Physicians is offering its fourth Medical Knowledge Self-Assessment Program (MKSAP IV). MKSAP IV is a sophisticated extension of its immediate predecessor. It consists of a syllabus that summarizes recent developments in 10 core areas of internal medicine followed by a self-assessment test and then a critique with answers, justification for answers, and references. A series of postgraduate courses that address themselves to the syllabus augment the program. MKSAP IV has been accepted with great enthusiasm by the community of internists, as indeed it should be. It is an outstanding effort in medical education... This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: ROBERT G. PETERSDORF, M.D., M.A.C.P.Affiliations: American Board of Internal Medicine American College of Physicians PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 May 1977Volume 86, Issue 5Page: 651-651KeywordsMedical education ePublished: 1 December 2008 Issue Published: 1 May 1977 PDF downloadLoading ...